liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Ethical Hurdles in the Prioritization of Oncology Care.
ToendersdeGroot B.V. Boomstede 281, 3608 AN, Maarssen, The Netherlands.
School of Economics and Management, LIUC University, Castellanza, Italy.
Independent Consultat, Bandol, France.
South East Commissioning Support Unit, London, UK.
Show others and affiliations
2017 (English)In: Applied Health Economics and Health Policy, ISSN 1175-5652, E-ISSN 1179-1896, Vol. 15, no 2, p. 119-126Article in journal (Refereed) Published
Abstract [en]

With finite resources, healthcare payers must make difficult choices regarding spending and the ethical distribution of funds. Here, we describe some of the ethical issues surrounding inequity in healthcare in nine major European countries, using cancer care as an example. To identify relevant studies, we conducted a systematic literature search. The results of the literature review suggest that although prevention, access to early diagnosis, and radiotherapy are key factors associated with good outcomes in oncology, public and political attention often focusses on the availability of pharmacological treatments. In some countries this focus may divert funding towards cancer drugs, for example through specific cancer drugs funds, leading to reduced expenditure on other areas of cancer care, including prevention, and potentially on other diseases. In addition, as highly effective, expensive agents are developed, the use of value-based approaches may lead to unacceptable impacts on health budgets, leading to a potential need to re-evaluate current cost-effectiveness thresholds. We anticipate that the question of how to fund new therapies equitably will become even more challenging in the future, with the advent of expensive, innovative, breakthrough treatments in other therapeutic areas.

Place, publisher, year, edition, pages
Springer, 2017. Vol. 15, no 2, p. 119-126
Keywords [en]
National Health Service Cancer Care Cancer Drug Disease Area Reimbursement Decision
National Category
Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-145714DOI: 10.1007/s40258-016-0288-4ISI: 000397244900001PubMedID: 27766548OAI: oai:DiVA.org:liu-145714DiVA, id: diva2:1191435
Available from: 2018-03-19 Created: 2018-03-19 Last updated: 2018-04-17

Open Access in DiVA

fulltext(459 kB)44 downloads
File information
File name FULLTEXT01.pdfFile size 459 kBChecksum SHA-512
531172374cd571de03c0165089fc8c8fca745ba25ff72a17f92ed1b1fbc0162f79743e0420fd241d026f2f9594c935ba389a32a93ae765fe3450574700c11c06
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Levin, Lars-Åke
By organisation
Division of Health Care AnalysisFaculty of Medicine and Health Sciences
In the same journal
Applied Health Economics and Health Policy
Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 44 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 93 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf